Pending U.S. legislative proposals include important biotechnology provisions such as the ORPHAN Cures Act, which addresses rare disease drug pricing and aims to restore incentives for developing treatments targeting multiple rare diseases. The bill also supports immediate R&D tax deductions critical to innovation funding and preserves orphan drug tax credits, representing a bipartisan effort to encourage personalized medicine and affordability without further jeopardizing the early-stage drug development pipeline.